Thank you for submitting your manuscript for consideration by The EMBO Journal, and please accept my apologies for the fact that it has taken us somewhat longer than usual to evaluate it. We have now received the reports of three referees, with the comments directly to the authors attached below. As you will see, all referees consider your findings potentially interesting and therefore suitable for publication in The EMBO Journal in principle. They do nevertheless raise a number of substantive points that would have to be satisfactorily addressed before publication. In particular, they all indicate that a somewhat better understanding of the roles of Sir3 as well as of the involvement of homologous recombination mechanisms would be important, and they propose a number of reasonable and concrete experiments to this effect.
In light of these overall positive evaluations and recommendations from the referees, I would like to invite you to prepare a revised version of the manuscript, taking into account the various issues and suggestions of the reviewers. Should you be able to adequately address their concerns and improve the manuscript through additional experimental evidence, we should be happy to consider a revised manuscript for publication. Please be reminded that it is EMBO Journal policy to allow a single round of revision only, and that it is therefore essential that you diligently answer to all the points raised at this stage if you wish the manuscript ultimately to be accepted. In any case, please do not hesitate to get back to us should you need feedback on any issue regarding your revision.
Thank you for the opportunity to consider your work for publication. I look forward to your revision. This manuscript explores the role of Sas2 histone acetyltransferase and its requirement for telomeric silencing on senescence in cells that are mutant for the tlc1 telomerase RNA. The authors find that loss of Sas2 delays senescence in tlc1 mutants and that telomere shortening in tlc1 mutant cells is accompanied by Sas2-dependent histone H4 lysine 16 (H4K16) acetylation. The provide evidence that Sas2 acts specifically through deacetylation of H4K16 to delay senescence through a mechanism that involves the release of Sir3 from telomeric repeat sequences. One surprising finding is that although deletion of SIR3 delays senescence in tlc1 mutant cells, deletion of SIR2 does not do so. The authors suggest that the release of Sir3 from telomeric repeats, but not subtelomeric silent domains, facilitates repair via homologous recombination.
The results are interesting and suggest a new role for the Sir3 silencing protein in regulation of telomere function. The experiments are logically designed and for the most part support the main conclusions of the paper. However, little is done to provide insight into the newly discovered role of Sir3, how this role might be uncoupled from its better known chromatin silencing functions, and how Sir3 association with telomeric repeats may impede homologous recombination and repair. A better understanding of some of these points would greatly strengthen the paper and is required for the paper to be suitable for a general audience journal such as EMBO.
The following specific points should be addressed.
1. The authors should take advantage of previously described Rap1 mutations that uncouple its telomere binding and maintenance functions from its Sir recruitment/silencing functions (from David Shore's lab). Rap1 mutations that disrupt Sir3 localization should also delay senescence in tlc1 mutant cells and would provide an additional test of the authors' model. Mutations in the Rap1-binding site in Sir3 would also be helpful. Along the same line, sir4 deletions should also be tested for their ability to delay senescence. Sir4 may help localize Sir3 to the Tel repeats or may be required downstream of Sir3 to delay senescence.
2. The authors should comment (in the Discussion section) how Sir3 localization to the Tel repeats may affect HR-mediated repair. As the authors note, the repeats are not packaged into nucleosomes, and since Sir2 is not required, this function of Sir3 is unlikely to be chromatin-mediated. Does Sir3 (and Sir4) affect association with the nuclear envelope and this in turn impedes recombination/repair? Minor points. 1. Figure 3B should include a positive control (a strain that's sensitive to HU, MMS, etc.). 2. Labels in the graph in Figures 6A and 7A are difficult to follow and should be modified.
Referee #2 (Remarks to the Author):
In this manuscript entitled "deletion of the sas2 histone acetyltransferase delays senescence driven by telomere dysfunction", Kozak and colleagues address the question of how chromatin structure impacts the signal emanating from eroded telomeres to induce replicative senescence. The authors show that loss of SAS2 increases the proliferation capacity of telomerase-negative cells. This discovery opened the way for further investigations on the role of chromatin in inducing senescence. The results indicate that that telomere shortening is accompanied by an increase of Sas2-dependent subtelomeric acetylation that mediates the release of Sir3 from this chromosome region. This is a very interesting work which is very well performed and controlled. I provide here some suggestions that could strengthen the authors conclusions.
Specific comments: -In p 8 the authors interpret the phenotype of the double rad52 sas2 as a suggestion for the fact that sas2-delta slows senescence through an HR-based mechanism. Although this can be possible, one can be more cautious and propose that HR loss is "dominant" over sas2 loss, meaning that sas2-deletion-driven alterations of the telomeres is useless in the absence of HR, which may also involve complete independence between both pathways. In general, this reviewer finds that all experiments in this work could be interpreted in an alternative way to "through the facilitation of HR". In particular the evidence that it does not modify the signalling of eroding telomeres is weak. The authors examine the role of the Sas2 histone acetyltransferase in cellular senescence. They show that loss of Sas2 in yeast cells also lacking telomerase (tlc1), delays the onset of senescence. Loss of the Sir3 protein also resulted in a similar delay in senescence. In the tlc1 sas2 mutants, subtelomeric H4K16 acetylation was lost. The authors hypothesized that this loss of H4K16 acetylation results in loss of Sir3 protein from the telomere repeats, which allows for HR-based repair at the telomeres and therefore a delay in cellular senescence. The data presented in this manuscript was well presented, thoroughly discussed and will be of general interest. This reviewer recommends publication in EMBO Journal following the revisions detailed below.
Comments:
1. Figure 3A . Please show a representative Southern blot beside the quantitated data.
2. Figure 4B . Is it possible to express SAS2 on a CEN plasmid in these cells? If so, please perform this rescue experiment as it will confirm that SAS2 activity is important for H4K16Ac at telomeres. Further to my recent decision letter, I am contacting you with some additional feedback on your manuscript. Your manuscript had initially been sent to four referees, but one of these referees was very much delayed in providing his/her comments even after several reminders sent by our office, so that I had -in light of the fair agreement of the other reviewers -eventually chosen to contact you with the decision to revise based on the three reports at hand. As it turns out, referee 4 has now sent a report after all, which is generally in line with the other reviewers' conclusion that your paper may in principle be suitable for publication in The EMBO Journal, but only after a substantial amount of revision.
Please note that given the final nature of my initial decision, the conclusion that successful revision of the paper will depend only on fully addressing the reports of referees 1-3 will stay unaffected by this additional set of comments; but given that the fourth referee has also invested time and effort into the review of your study, and that you may want to take into account some of the suggestions made to further strengthen your revised manuscript, I thought I should transmit them to you nevertheless. I hope you will find them useful.
Best regards,
Editor
The EMBO Journal In their manuscript, Kozak et al study the effect of Sas2 on senescence in yeast lacking telomerase activity, thus giving insight into the role of chromatin in telomere shortening and associated senescence. The authors demonstrate that deletion of SAS2 delays senescence through loss of H4 AcK16 in vivo. They also demonstrate that this effect functions through HR and loss of Sir3. These findings are important and bring new information on the role of chromatin at telomeric regions in modulating telomere shorthening-induced senescence. Because of the mass of data present in the literature on the different players involved in defining telomeric chromatin structure, it feels like the proposed model could be right but some important experiments and other obvious players could be investigated to provide with a clear mechanism.
Major points -It is known that Sas2-dependent K16 acetylation displaces Sir3 but also allows Dot1 to bind and methylate H3 K79 which in turn also blocks Sir3 from binding. Through this succession of events, Sas2 is more critical than Dot1 in displacing Sir3. But H3 K79me is essential for Rad9 binding to chromatin and function in tight control of DDR, including at uncapped telomeres. Thus, it would be interesting to investigate the role of Dot1/K79A mutants and Rad9 in the senescence kinetic of tlc1-sas2. (I understand that Rad53 is normally phosphorylated in the cdc13-1-sas2 strain at 30C, but I would like to see if dot1/K79A or rad9 mutants can have a similar effect on sas2-induced delayed senescence, like sir3/K16R or rad51/52 do. Suppl Fig4 with tlc1-dot1 double mutant is supporting such line of experiments)
- Figure 3 Panel B: DNA damage sensitivity could be tested under more stringent conditions, such as synthetic complete media. Panel C, D: There is a very clear suppression of cdc13-1 at 28C. The authors need to perform the P-Rad53 western at 28 degrees as well (not only at 30 where there is no suppression) to determine a putative checkpoint defect that could partially explain the delay in senescence. This is very important in part because of SupplFigure4. As seen by this figure, Dot1 seems to have a role in senescence. The authors conclude that Dot1 acts in a similar mechanism as Sas2; but Dot1 has a verified role in checkpoint signalling in response to telomere uncapping. How do the authors explain their findings considering the checkpoint role of Dot1? Could the same be happening with Sas2? Is what we see just a checkpoint defect, given that Sas2 might have a role in checkpoint signalling through regulation of Dot1/Rad9 binding (see above comment)?
Figure 6 Panel A: a sir3 single mutant control is required.
Discussion
The discussion is quite long at 8 pages. If Sir3 has no apparent role in global HR (page 19, line 14-15), then why do the authors conclude that the effect seen in senescence is due to HR-dependent telomere repair? How is Sas2 involved in HR? Are the recombination events at telomeres of tlc1 sas2 strains indeed more frequent than in tlc1?
The authors should include the tlc1 sir2 strain in their model (Fig. 8 ) to clarify the model.
Other points:
-Sas2 was clearly shown to be responsible for K16 acetylation in vivo (Horikoshi's and Grunstein's reports) but the reported weak activity on H3 K14 was only reported in vitro with non-physiological substrates. The text about Sas2-AcK14 could be removed and the H3 AcK14 ChIPs could simply be kept as control. The effect of sas2 mutant on AcK14 is most likely indirect through Gcn5 or Sas3, the two HATs responsible for this mark. Have the authors looked at ERC formation in tlc1 sas2/sir3 strains? What would the effect be?
Could there be alternative ways that Sas2 affects senescence? Does Sas2 acetylate any Sir protein or an HR protein?
Minor points:
Title: use correct nomenclature, if you are talking of deletion of a gene, SAS2 should be uppercase and italicised. Specific Remarks:
The authors should take advantage of previously described Rap1 mutations that uncouple its telomere binding and maintenance functions from its Sir recruitment/silencing functions (from David Shore's lab). Rap1 mutations that disrupt Sir3 localization should also delay senescence in tlc1 mutant cells and would provide an additional test of the authors' model. Mutations in the Rap1-binding site in Sir3 would also be helpful. Along the same line, sir4 deletions should also be tested for their ability to delay senescence. Sir4 may help localize Sir3 to the Tel repeats or may be required downstream of Sir3 to delay senescence.
We agree with the reviewer that we had not done enough to understand the role of Sir3 in the regulation of telomere recombination. We have obtained the following results from new experiments to address this issue. First, we demonstrated by ChIP that lower levels of Sir3 are present at the telomere end in senescing tlc1 sas2 than in tlc1 mutants (Fig. 6B) , consistent with our model that removal of Sir3 from the telomere repeats is important for delayed senescence. Second, by using telomere PCR to amplify telomeres from senescing cells, and then cloning and sequencing individual examples, we measured directly the levels of telomere recombination, and found that it is indeed elevated in tlc1 sas2 cells compared with matched tlc1 cells (Figs. 2C & D) . Third, we have examined the role of Sir4 during senescence. Remarkably (and as predicted by the reviewer as a possible outcome), tlc1 sir4 mutants senesce more rapidly than tlc1 mutants, and sir4 deletion prevents sas2 or sir3 deletion from slowing senescence (Figs. 7B & C). We speculate that the known role of Sir4 in anchoring telomeres to the nuclear periphery (which it is known to do in a fashion independent of Sir2 and Sir3) is important for enabling beneficial telomere recombination. Furthermore, because Sir3 binds Sir4 as well as Rap1, this raises the possibility that the inhibitory effect of Sir3 involves interference with a beneficial role for Sir4 and/or Rap1 in the proposed recombination pathway. The opposing roles of Sir3 and Sir4, together with the fact that there are pair-wise physical interactions between Sir3, Sir4 and Rap1 make it challenging to dissect precisely how different interaction surfaces between the proteins contribute to their effects during senescence. For example, a mutation in Rap1 that disrupts its binding to Sir3 might slow senescence by releasing Sir3, but it might speed senescence if it also releases Sir4; Rap1 mutants that disrupt Sir3 binding exist (Moretti et al., 1994 Genes Dev.; Cockell et al., 1995 JCB; Liu and Lustig, 1996 Genetics; Moretti and Shore, 2001 MCB; Feeser and Wolberger, 2008 JMB) , but their effects on Sir4 are poorly characterized, making this a non-trivial experiment. Additionally, mutations that disrupt binding of Sir3 to Rap1 might still allow Sir3 to speed senescence via interaction with Sir4; combined disruption of Sir3-Rap1 and Sir3-Sir4 interactions might be required to fully liberate Sir3. Furthermore if the consequences of Sir3 loss (via sir3 or sas2 deletion) are to uncover a surface on Rap1 and/or Sir4 that plays an active role in slowing senescence, then by mutating residues within these surfaces to disrupt Sir3 binding, the beneficial effects of the surfaces could be lost (thus on the one hand, one might predict that a Rap1 or Sir4 mutation that releases Sir3 should slow senescence, but on the on the other hand it might be expected to speed senescence). We agree with the reviewer that these are important experiments, and have indeed begun to carry them out and will continue to pursue them. However, because our findings are not yet conclusive and because a detailed understanding is likely to involve many experiments, we respectfully request that we be allowed to save them for a different manuscript. As requested by the reviewer, we comment in the Discussion about possible roles for Sir4 and Sir3 in relation to telomere anchoring at the nuclear envelope. This month, Khadaroo et al. (Nat Cell Biol. 2009 Aug; 11(8) :980-7) published findings indicating that telomeres translocate to the nuclear pore complexes in senescence telomerase mutants, and we discuss our findings in relation to theirs. We plan to use the techniques described in their publication in future experiments to test these ideas. Also, we understand the Reviewerís point about the telomere not containing nucleosomal chromatin, but we do want to point out that it is standard in the literature for the nucleoprotein structure comprising Rap1, the Sir complex and telomere repeat DNA to be considered a type of 'heterochromatin'. However, we now emphasize in the Discussion that the role of these proteins at the telomere repeats does not involve classical nucleosomal chromatin, and clarify the presentation of our model that the Sas2-mediated effects on subtelomeric chromatin have indirect effects on the telomere repeat region (via loss of Sir3).
The authors should comment (in the Discussion
Minor points.
Figure 3B should include a positive control (a strain that's sensitive to HU, MMS, etc.).
We have repeated the experiment and included rad52 mutants, which are sensitive to the genotoxins. In addition, we broadened our test to include X-irradiation, 4-NQO, and tests on synthetic medium (which might have elicited a subtle defect); Supplemental Fig. 4 . It remains clear that deletion of SAS2 does not increase sensitivity to DNA damaging agents. Figures 6A and 7A are difficult to follow and should be modified.
Labels in the graph in
We have modified the symbols and lines so that it is easier to visualize the data in these graphs. We thank the reviewer for this helpful suggestion. We compared the senescence rates of tlc1, tlc1 tel1, tlc1 sas2, and tlc1 sas2 tel1 mutants (each genotype derived from a triply heterozygous diploid) and found that the sas2 and tel1 deletions each slowed the senescence of tlc1 mutants, as expected. Remarkably the tlc1 sas2 tel1 mutants had dramatically slowed senescence, with the effects of the sas2 and tel1 mutations combining in an additive fashion (Fig. 3C) . Thus the sas2 and tel1 mutations most likely affect separate processes. If Tel1 promotes signaling from eroded telomeres, either directly or indirectly (e.g. via Mec1; as proposed in an article published this month by Abdallah et al., Nat Cell Biol. 2009 Aug; 11(8):988-93) , then the result clearly supports our interpretation that the sas2 deletion is not affecting this signaling. We also want to point out that the results of this experiment for the first time indicate that there are may be at least two genetic pathways that can be manipulated to slow senescence.
2-Is the type of HR events altered in sas2 tlc1 cells? To address this question the authors can sequence the telomeres in these cells and proceed to a similar analysis as in their previous work (Lee et al Plos Biol 2007).
We thank the reviewer for this excellent suggestion. We cloned and sequenced telomeres from senescing tlc1 and tlc1 sas2 mutants. Whether matched for population doubling or degree of senescence (arguments can be made for either type of comparison), the tlc1 sas2 mutants had statistically significantly higher levels of telomere recombination events that tlc1 controls (31% or 39% compared with 15% recombinants (p = 0.045 or 0.005), respectively; Figs 2C and 2D). Importantly, each recombinant telomere reflected an independent recombination event, and so there was no skewing of the data by 'jackpot' recombination events that could have happened earlier during senescence. These data support our model that sas2 deletion facilitates HR-dependent repair of shortening telomeres. Even though the two experiments suggested by the reviewer support our model, and we do believe that it is the simplest model to explain our findings, we do agree with the reviewer that our data do not exclude other models, and we have therefore softened our interpretation concerning the potential role of HR. For example, in the Discussion, we have added the following:
'We favor the idea that the increased telomere recombination explains the slowed senescence, but it is possible that it is merely correlated with it. Further, the Rad51 and Rad52-dependence of delayed senescence might reflect senescence in tlc1 rad51 and tlc1 rad52 mutants that is so rapid as to preclude benefit from sas2 deletion, rather than reflecting a bona fide role for HR in sas2 cells. It is difficult to completely rule out this alternative interpretation, but we note that the defect in tlc1 rad51/52 mutants is mild enough to permit over 55 PD prior to senescence. Also, in the cdc13-1 model, where sas2 deletion also confers a Rad52-dependent growth benefit at semi-permissive temperature, the growth defect of cdc13-1 rad52 mutants is no worse than that of cdc13-1 mutants (Fig. 3C) , and thus the Rad52-dependence for improved telomere maintenance need not reflect a growth defect.' In addition, we want to mention that have recently identified a genetic manipulation that significantly slows the senescence of tlc1 rad52 mutants ( > 10PD; G. Logsdon, J. Wannat and FBJ, unpublished), indicating no absolute barrier to delaying senescence in these mutants.
Referee #3:
The We now provide representative data in Supplemental Figure 2 . We wish to emphasize that the mean telomere lengths of senescent tlc1 sas2 mutants are only ~ 20 bp shorter than those of senescent tlc1 mutants. Because the XhoI fragment that is visualized by Southern analysis is approximately 1 kb in senescent cells, this is a difference of only 2%, which is difficult to visualize. However, our objective measurement of telomere lengths, using pixel-level resolution and a weighted average using the formula (ODi x lengthi)/ (ODi) (rather than using a visual estimate of the middle of a smear as is often done), among 14 comparisons each derived from the same tetrad, allowed us to discern this small difference. We have placed these data in Supplemental Material, because this provides an opportunity to point out these details, whereas if placed in the main text, a cursory examination without the explanation might lead a reader to conclude incorrectly that there is no difference in telomere length between the genotypes at senescence.
2. Figure 4B . Is it possible to express SAS2 on a CEN plasmid in these cells? If so, please perform this rescue experiment as it will confirm that SAS2 activity is important for H4K16Ac at telomeres.
We agree that it is important to be certain that Sas2 is responsible for acetylation of H4K16 at subtelomeric sites. However we have not performed the suggested experiment because direct acetylation of H4K16 by Sas2 has been extensively documented (Shia et al., 2005, JBC; Sutton et al., 2003; JBC) , targeted loss of SAS2 results in decreased acetylation near the telomere (Kimura et al., 2002 Nat. Gen.; Suka et al. 2002, Nat. Gen) and overexpression of Sas2 causes increased H4K16 acetylation near the telomere (Altaf et al., 2007 Mol. Cell) . Further several lines of evidence in our manuscript support the direct action of Sas2 on H4K16. First, deletion of the locus encoding Sas4, which is known to function in complex with Sas2, recapitulated the delayed senescence observed sas2 mutants (Fig. 1B) . Second, as assayed by ChIP, H4K16 levels decreased in response to sas2 deletion (Fig. 4B) . Third, mutation of H4K16 from lysine to arginine abrogates delayed senescence seen with wild type lysine 16 (Fig. 5) . Fourth, we have also added a new experiment in Supplemental Fig. 7 providing evidence that sas2 deletion slows senescence in tlc1 mutants carrying the H3K14R allele (in contrast with senescence in cells carrying H4K16R, which is not slowed by sas2 deletion). Thus, even though Sas2 has some ability to acetylate H3K14, it is the acetylation of H4K16 by Sas2 that impacts senescence. We hope that the reviewer will agree that this new experiment is actually more informative than returning SAS2 on a plasmid to a sas2 deletion strain.
Figure 4. Additional ChIP data showing loss of Sir3 from telomeres in tlc1 sas2 mutant cells would further support the authors' central hypothesis that loss of H4K16 acetylation results in loss of Sir3 protein from the telomere repeats.
We thank the reviewer for this helpful suggestion, and we provide the requested data in Fig 6B. Consistent with our hypothesis, we find that more Sir3 is lost from telomeres in senescent tlc1 sas2 mutant cells than in tlc1 controls.
If possible, ChIP data showing the appearance of factors involved in HR-based repair at telomeres in tlc1 sas2 mutants versus tlc1 mutants alone would be desirable.
We agree with the reviewer that these are important experiments, and we plan to pursue them. However, we have not yet attempted the experiments because we were concerned that there might be too many experimental barriers to overcome in the short time period provided prior to submission of our revised manuscript. The first evidence for the association of HR factors with telomeres by ChIP in senescent yeast telomerase mutants was published only this month (Khadaroo et al. Nat Cell Biol. 2009 Aug; 11(8) :980-7), and these findings suggest that we should be able to perform these experiments in the coming year. We hope that the reviewer will allow us to save this work for a future manuscript.
